Development and validation of novel ultraviolet spectrophotometric method for estimation of antileishmanial drug buparvaquone

Shaikh, T. K. and Shelke, S. S. and Kakde, I. R. and Lalatsa, Aikaterini and Kakde, R. B. (2022) Development and validation of novel ultraviolet spectrophotometric method for estimation of antileishmanial drug buparvaquone. Indian Journal of Pharmaceutical Sciences, 84 (1). pp. 130-136. ISSN 1998-3743 (https://doi.org/10.36468/pharmaceutical-sciences.9...)

[thumbnail of Shaikh-etal-2022-Development-and-validation-of-novel-ultraviolet-spectrophotometric]
Preview
Text. Filename: Shaikh_etal_2022_Development_and_validation_of_novel_ultraviolet_spectrophotometric.pdf
Final Published Version
License: Creative Commons Attribution-NonCommercial-ShareAlike 3.0 logo

Download (599kB)| Preview

Abstract

A novel, simple, accurate, precise, economical and reliable ultraviolet spectrophotometric method has been developed for the estimation of buparvaquone in bulk and in pharmaceutical dosage form. The drug shows maximum absorption at 251 nm by using acetonitrile as solvent. The method was validated as stated in International Council for Harmonisation Q2 (R1) guidelines. It obeys Beer's law in the concentration range of 2-20 µg/ml with correlation coefficient of 0.998. The drug shows great accuracy close to 100 %. The method was found to be robust and precise as the relative standard deviation are less than 2 %. Limit of detection and limit of quantitation were found to be 0.60 µg/ml and 1.83 µg/ml respectively. From the results of specificity, the drug was found to be more degraded under alkaline, oxidative and photolytic conditions. The proposed method can be employed for the reliable quantification of buparvaquone in bulk and routine analysis of pharmaceutical formulations.